Abstract:Abstract Background Tumor-infiltrating immune cells are present in various malignant tumors, but their clinical significance in gastric cancer (GC) remains unclear. This study aimed to investigate the prognostic significance of tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). Methods Using a prospective database containing 401 cases of GC, we evaluated TIL (cluster of differentiation 8 (CD8) expression) and TAM (cluster of differentiation 68 (CD68) expression) statuses via immunohistochemical staining. Results Compared with CD8+ TIL-negative cases ( n = 196, 48.6%), CD8+ TIL-positive cases ( n = 205, 51.1%) showed significantly better recurrence-free survival (RFS) [log-rank p <0.001; multivariate HR: 0.372; 95% confidence interval (CI): 0.239–0.579, p <0.001]. In contrast, compared with CD68+ TAM-negative cases ( n = 217, 54.1%), CD68+ TAM-positive cases ( n = 184, 45.9%) had significantly poor RFS [log-rank p <0.001; multivariate HR: 2.182; 95% CI: 1.435–3.318, p <0.001]. Thus, patients with a positive CD8+ TIL and negative CD68+ TAM status exhibited significantly increased RFS. Multivariate analysis demonstrated that CD8+ TILs and CD68+ TAMs may serve as independent prognostic markers for RFS. Incorporating CD8+ TIL and CD68+ TAM statuses into the AJCC TNM system generated a predictive model with better predictive accuracy for RFS. More importantly, patients with a positive TIL and negative TAM status showed a tendency of improved RFS after postoperative adjuvant chemotherapy (PAC). Similar results were obtained by overall survival (OS) analysis. Conclusions CD8+ TIL and CD68+ TAM statuses were identified as independent prognostic factors that may be integrated into the current TNM staging system to refine risk stratification and to better predict the survival benefit from PAC in patients with GC. Trial registration The current controlled trial was registered at ClinicalTrials.gov (ID: NCT02327481 ) on December 30, 2014.

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

High infiltration of mast cells associates with improved response to adjuvant chemotherapy in gallbladder cancer.

Tumor Stroma-Infiltrating Mast Cells Predict Prognosis and Adjuvant Chemotherapeutic Benefits in Patients with Muscle Invasive Bladder Cancer.

Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Mast Cell Density in Metastatic Renal Cell Carcinoma: Association with Prognosis and Tumour‐infiltrating Lymphocytes

Stathmin 1 Expression Predicts Prognosis and Benefits from Adjuvant Chemotherapy in Patients with Gallbladder Carcinoma.

Identification of Tumor-Infiltrating Immune Cells and Prognostic Validation of Tumor-Infiltrating Mast Cells in Adrenocortical Carcinoma: Results from Bioinformatics and Real-World Data

Tumor‐infiltrating Neutrophils Predict Prognosis and Adjuvant Chemotherapeutic Benefit in Patients with Biliary Cancer

Integrated analysis of immune infiltration in esophageal carcinoma as prognostic biomarkers

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Prognostic Significance of CD11b-, CD8-, and CD163-Positive Tumor-Infiltrating Immune Cells in Distal Bile Duct Cancer

Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer.

Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)

TIM3+ cells in gastric cancer: clinical correlates and association with immune context

The Tumor Microenvironment in Gastrointestinal Adenocarcinomas Revealed a Prognostic and Immunotherapeutic Biomarker.

Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer

CD19(+) Tumor-Infiltrating B-cells Prime CD4(+) T-cell Immunity and Predict Platinum-Based Chemotherapy Efficacy in Muscle-Invasive Bladder Cancer

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

Combination of Peritumoral Mast Cells and T-regulatory Cells Predicts Prognosis of Hepatocellular Carcinoma.

Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients